Last week, the FTC announced an investigation of six large PBMs in the U.S., sending orders for information and records on business practices. The study will focus on a series of practices used by PBMs and their role in the drug system. The agency said its investigation will examine possibly unfair audits of independent pharmacies, the impact of drug rebates, specialty drug policies and fees or clawbacks charged to pharmacies not affiliated with the PBM.
Frier Levitt attorney A.J. Barbarito shared his insight of the PBM industry, FTC’s investigation and how the investigation’s findings may impact the industry in a Fierce Healthcare article, “Experts Say Broad FTC Probe Could Bring New Crackdown and Laws on PBM Industry, ” by Robert King.
“If the FTC does determine that PBMs are unfairly advantaging their own wholly owned pharmacies they may seek some kind of injunction to prevent them from continuing to engage in those activities,” Barbarito said.
Read the article here: https://bit.ly/3zwwev5
